Breast Cancer Clinical Trial
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
Summary
This study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life and function, 3 years or more after the treatment, in cancer-free subjects.
There will be 2 groups. Cohort A: Women who participated in previous studies namely NCT02167932, NCT02328313, and NCT03761706, will be re-contacted and consent for this study activities. Cohort B: Women with breast cancer, who did not receive chemotherapy, will be consented to be included in the study, and their electronic medical data will be used.
Furthermore, the long-term effects of treatment and a biomarker of aging cyclin-dependent kinase inhibitor 2A (CDKN2A,p16INK4a) and relation will be assessed.
Eligibility Criteria
Inclusion Criteria:
In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
Informed consent was obtained per Institutional Review Board guidelines to participate in the study and HIPAA authorization for the release of personal health information.
Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.
Age ≥21 years at the time of consent.
Able to read and comprehend English.
No breast cancer recurrence or metastasis; no other cancer diagnosis other than basal cell or squamous cell cancers.
Exclusion Criteria:
Unable to read or comprehend English.
Breast cancer recurrence or metastasis; any other cancer diagnosis other than basal cell or squamous cell cancer.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chapel Hill North Carolina, 27599, United States More Info
Principal Investigator
How clear is this clinincal trial information?